Blair William & CO Grifols Sa Transaction History

Blair William & CO

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$10.21 - $15.27 $121,233 - $181,315	-11,874 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$16.62 - $18.94 $216 - $246	-13 Reduced 0.11%	11,874 $206,000
Q1 2021 May 13, 2021	BUY	$15.15 - $19.78 $196 - $257	13 Added 0.11%	11,887 $206,000
Q4 2020 Feb 09, 2021	SELL	$16.86 - $19.67 $219 - $255	-13 Reduced 0.11%	11,874 $219,000
Q3 2020 Nov 06, 2020	SELL	$15.4 - $20.16 $55,301 - $72,394	-3,591 Reduced 23.2%	11,887 $206,000
Q2 2020 Aug 12, 2020	SELL	$18.24 - $21.45 $1.4 Million - $1.65 Million	-76,749 Reduced 83.22%	15,478 $282,000
Q1 2020 May 11, 2020	BUY	$16.28 - $25.63 $7,244 - $11,405	445 Added 0.48%	92,227 $1.86 Million
Q4 2019 Feb 13, 2020	BUY	$19.57 - $23.52 $1.48 Million - $1.78 Million	75,858 Added 476.38%	91,782 $2.14 Million
Q2 2019 Aug 13, 2019	SELL	$17.59 - $21.1 $7,036 - $8,440	-400 Reduced 2.45%	15,924 $336,000
Q1 2019 May 14, 2019	SELL	$18.01 - $20.11 $25,556 - $28,536	-1,419 Reduced 8.0%	16,324 $328,000
Q4 2018 Feb 14, 2019	SELL	$17.44 - $21.53 $14,806 - $18,278	-849 Reduced 4.57%	17,743 $326,000
Q3 2018 Nov 13, 2018	SELL	$19.97 - $21.96 $17,973 - $19,764	-900 Reduced 4.62%	18,592 $397,000
Q2 2018 Aug 13, 2018	SELL	$20.16 - $24.68 $392,474 - $480,470	-19,468 Reduced 49.97%	19,492 $419,000
Q1 2018 May 15, 2018	BUY	$20.31 - $24.95 $71,064 - $87,300	3,499 Added 9.87%	38,960 $826,000
Q4 2017 Feb 14, 2018	SELL	$20.99 - $23.89 $128,605 - $146,374	-6,127 Reduced 14.73%	35,461 $813,000
Q3 2017 Nov 13, 2017	BUY	$20.07 - $21.89 $834,671 - $910,361	41,588	41,588 $910,000

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.33B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.